Delving into the Latest Updates on SHR-1826 with Synapse

Overview

Basic Info

Drug Type

Antibody drug conjugate (ADC)

Synonyms

SHR 1826, SHR1826

Target

c-Met

Action

inhibitors

Mechanism

c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

Solid tumorAdvanced Lung Non-Small Cell CarcinomaAdvanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active Organization

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Shandong Suncadia Medicine Co., Ltd.Startup

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

This study is a multicentre, open phase II clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in combination with antitumor drugs in subjects with advanced malignant tumour. To evaluate the safety, tolerability and efficacy of HRS-7058 in combination with antitumor drugs.

Start Date01 Apr 2025

Sponsor / Collaborator

Shandong Suncadia Medicine Co., Ltd.Startup

CTR20250604

/ RecruitingPhase 2

注射用SHR-1826联合方案治疗晚期非小细胞肺癌患者的安全性、耐受性和有效性的多中心、开放的Ⅱ期临床研究

[Translation] A multicenter, open-label phase II clinical study on the safety, tolerability and efficacy of SHR-1826 injection combined with other regimens in the treatment of patients with advanced non-small cell lung cancer

主要目的：评估SHR-1826联合其他抗肿瘤治疗在晚期非小细胞肺癌受试者中的安全性、耐受性和客观缓解率。次要目的：评估SHR-1826联合其他抗肿瘤治疗在晚期非小细胞肺癌中的其他有效性终点、PK特征及免疫原性。

[Translation]

Primary objective: To evaluate the safety, tolerability and objective response rate of SHR-1826 combined with other anti-tumor therapies in subjects with advanced non-small cell lung cancer. Secondary objective: To evaluate other efficacy endpoints, PK characteristics and immunogenicity of SHR-1826 combined with other anti-tumor therapies in advanced non-small cell lung cancer.

Start Date07 Mar 2025

Sponsor / Collaborator

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

100 Clinical Results associated with SHR-1826

Login to view more data

100 Translational Medicine associated with SHR-1826

Login to view more data

100 Patents (Medical) associated with SHR-1826

Login to view more data

100 Deals associated with SHR-1826

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Solid tumor	Phase 2	China	Shandong Suncadia Medicine Co., Ltd.Startup	01 Apr 2025
Advanced Lung Non-Small Cell Carcinoma	Phase 2	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	07 Mar 2025
Advanced Malignant Solid Neoplasm	Phase 2	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	18 Feb 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data